# Effect of Caffeine Consumption on Protein Biomarkers and Cardiovascular Disease

> **NCT06359197** · EARLY_PHASE1 · UNKNOWN · sponsor: **Hamilton Health Sciences Corporation** · enrollment: 36 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Caffeine Pill
- **DRUG:** Placebo
- **DEVICE:** TASSO+ Device
- **DEVICE:** Finger prick and collection on Whatman Protein 903 Saver Cards
- **DEVICE:** Intravenous Sampling

## Key facts

- **NCT ID:** NCT06359197
- **Lead sponsor:** Hamilton Health Sciences Corporation
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-08
- **Primary completion:** 2024-08-10
- **Final completion:** 2025-06-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06359197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06359197, "Effect of Caffeine Consumption on Protein Biomarkers and Cardiovascular Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06359197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*